Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days
Open Access
- 1 January 1990
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 34 (1) , 150-152
- https://doi.org/10.1128/aac.34.1.150
Abstract
We evaluated the effect of repeated oral doses (5 days of treatment) on the kinetics of lomefloxacin in volunteers and compared the kinetics after two different regimens, i.e., 400 mg once daily and 200 mg twice daily. After 400 mg of lomefloxacin was given once daily, no significant modification in the pharmacokinetic parameters was noted between the first and the fifth dose (maximum concentration of drug in serum, about 4 mg/liter; elimination half-life, about 6.3 h). After a dose of 200 mg every 12 h, a significant increase in the minimum concentration of drug in serum (0.49 +/- 0.1 and 0.72 +/- 0.2 mg/litter at days 1 and 5, respectively) and the area under the concentration-time curve (about 20%) was noted. The 400-mg regimen is probably adequate for therapeutic use.This publication has 6 references indexed in Scilit:
- Pharmacokinetics and tissue penetration of orally administered lomefloxacinAntimicrobial Agents and Chemotherapy, 1988
- Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral dosesAntimicrobial Agents and Chemotherapy, 1988
- In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolonesAntimicrobial Agents and Chemotherapy, 1988
- In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agentsAntimicrobial Agents and Chemotherapy, 1988
- Clinical Pharmacokinetics of the Newer Antibacterial 4-QuinolonesClinical Pharmacokinetics, 1988
- In vitro and in vivo activity of NY-198, a new difluorinated quinoloneAntimicrobial Agents and Chemotherapy, 1987